CAS: 58767-51-4; 1H-Imidazole-4-Sulfonyl Chloride

相似化合物

137049-00-4 1416352-08-3 2839156-62-4

上下游产品

CAS号60634-74-4 1H-imidazole-5-...

📜1H-咪唑-5-磺酸置于氯化亚砜体系中,用30.2 G的收率获得产物咪唑-4-磺酰氯
参考文献:Design And Synthesis Of An Fmoc-Spps-Compatible Amino Acid Building Block Mimicking The Transition State Of Phosphohistidine Phosphatase
标题:Design And Synthesis Of An Fmoc-Spps-Compatible Amino Acid Building Block Mimicking The Transition State Of Phosphohistidine Phosphatase
摘要:The Synthesis Of A Sulfonamide-Based Transition-State (Ts) Analogue Of Enzymatic Phosphohistidine Dephosphorylation As An Amino Acid Building Block Is Presented,Together With The Proof-Of-Concept Of Its Incorporation Into Peptides. Key Features Include Final Global Acidolytic Protective Group Removal As Well As Full Compatibility With Standard Fmoc Solid-Phase Peptide Synthesis (Spps). The Peptides Are Designed As Inhibitors Of Phosphohistidine Phosphatase And As A Pull-Down Probe For Identification Of Phosphohistidine Phosphatases,Respectively.
DOI:10.1021/jo2025702

专利信息

专利号:WO-2023039068-A1
优先权日:2021-09-08
标题:Compositions and methods for synthesis of peptide nucleic acid intermediates
发明人：COULL JAMES M; GILDEA BRIAN D
权利人:NEUBASE THERAPEUTICS INC
摘要:The present disclosure provides intermediates for the synthesis of peptide nucleic acid (PNA) backbones and monomers, such as cyclic intermediates, and methods of making the same.

专利号:US-10316018-B2
优先权日:2015-08-27
标题 :Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
发明人：LEE KATHERINE LIN; ALLAIS CHRISTOPHE PHILIPPE; DEHNHARDT CHRISTOPH MARTIN; GAVRIN LORI KRIM; HAN SEUNGIL; HEPWORTH DAVID; LEE ARTHUR; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; OWEN DAFYDD RHYS; PAPAIOANNOU NIKOLAOS; SAIAH EDDINE; STROHBACH JOSEPH WALTER; TRZUPEK JOHN DAVID; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.